Last reviewed · How we verify
NCT06850571
Aflibercept and Bevacizumab for Diabetic Maculopathies
Phase 4 trial testing Bevacizumab Injection [Avastin] in Diabetic Maculopathy in 102 participants. Currently enrolling.
1 December 2025
Quick facts
| Lead sponsor | Al-Mustansiriyah University |
|---|---|
| Phase | Phase 4 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 102 |
| Start date | 20 February 2025 |
| Primary completion | 1 December 2025 |
| Estimated completion | 1 December 2025 |
| Sites | 1 location across Iraq |
Drugs / interventions tested
- Bevacizumab Injection [Avastin]
- Aflibercept 2Mg/0.05Ml Inj,Oph — full drug profile →
Conditions studied
- Diabetic Maculopathy — all drugs for Diabetic Maculopathy →
Sponsor
Al-Mustansiriyah University
Who can join
40 and older, any sex, with Diabetic Maculopathy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to to evaluate the clinical outcomes following treatment with bevacizumab versus aflibercept. These outcomes include: * Functional changes: The visual outcomes achieved by testing visual acuity * Anatomical changes: macular thickness and edema by optical coherence tomography (OCT).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06850571
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Bevacizumab Injection [Avastin]
Trials testing the same drug.
- NCT03950154 — Study of Chemotherapy Combination With Autologous Cell Immunotherapy in the Recurrent and Metastatic Colorectal Cancer · Phase 3 · unknown
- NCT06559488 — IVB for Post-vitrectomy Hemorrhage in Diabetic Eyes · NA · completed
- NCT05514925 — Cryoapplication Versus Anti-VEGF Before Diabetic Vitrectomy · Phase 4 · unknown
- NCT03211741 — Longterm Efficiency and Safety of Intravitreal Injections With Bevacizumab in Patients With Neovascularisation or Macula · Phase 4 · unknown
Other Al-Mustansiriyah University trials
Trials by the same sponsor.
- NCT07375004 — Injectable PRF in Non-Surgical Periodontal Treatment · NA · active not recruiting
- NCT06921434 — the Effect of Monk Fruit and Splenda on Salivary Ph and Streptococcus Mutans Count in Vivo Study · NA · not yet recruiting
- NCT07182526 — Effects of Adding Quercetin or Alpha Lipoic Acid to Usual Care on Symptoms and Blood Markers in Iraqi Women With Polycys · Phase 2 · recruiting
- NCT07493291 — Effectiveness and Safety of Palbociclib: Brand vs. Generic in Iraqi Stage IV Breast Cancer Patients · active not recruiting
- NCT07020078 — Oral Health Condition Among a Group of Ionizing Radiation Field Workers · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06850571 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Al-Mustansiriyah University
- Last refreshed: 19 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06850571.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing